ICSI Guideline Lipid Management in Adults
Search this site
Navigation
Home
Response Report 2009
Summary of Changes
Executive Summary
Algorithm
Foreword
Work Group
Document History
Disclosure of Potential Conflicts of Interest
Introduction to ICSI Document Development
Supporting Evidence and Description of Evidence Grading
Algorithm Annotations
1. Patient Has Dyslipidemia or Is at High Risk for Coronary Heart Disease (CHD)
2. Initiate Lifestyle Modifications
Diet
Aerobic exercise
Weight management
Smoking cessation
Evaluation of alcohol consumption
Sterol and stanol ester nutritional supplement
Fish oil (EPA-DHA)
3. Calculate 10-Year Risk for CHD or Add Up Cardiac Risk Factors
8. Drug Therapy
Statin Therapy Management
Statin Safety and the Muscle
Patients Unable To Use Statin Therapy
Aspirin
9. LDL Goal Met?
10. Address Adherence and Life Style Modifications
12. Laboratory Monitoring in 3-12 months
13. Health Maintenance
14. Evaluation and Management of Elevated Triglycerides and/or Low HDL
16. Follow-up
Conclusion Grading Worksheet Summary
Conclusion Grading Worksheet A
Conclusion Grading Worksheet B – (History of CHD)
References
Aims and Measures
Key Implementation Recommendations and Knowledge Resources
Shared Decision-Making Resouces
Appendices
Appendix A – Omega-3 Fatty Acids
Appendix B - Identified Secondary Causes and Conditions Associated with Hyperlipidemia
Appendix C - Drug Companion Document
Appendix C – Drug Companion Document – Treatment Options
Appendix C – Drug Companion Document – Statins
Appendix C – Drug Companion Document – Fibric Acids
Appendix C – Drug Companion Document – Niacin
Appendix C – Drug Companion Document – Ethyl Esters of Omega-3 Fatty Acids
Appendix C – Drug Companion Document – Selective Cholesterol Absorption Inhibitors
Appendix C – Drug Companion Document – Bile Acid Sequestrants
Appendix C – Drug Companion Summary Table
Appendix D – NCEP Recommendations on Strategies to Improve Adherence
Sitemap
12. Laboratory Monitoring in 3-12 months
Obtain a fasting lipid panel or lipid panel with direct LDL and transaminase as indicated (or see drug insert or drug companion)
(McKenney, 2001b [R])
.
Refer to
Appendix C, "Drug Companion Document."
Comments
_displayNameOrEmail_
- _time_ -
Remove
_text_